Viewing Study NCT02608268

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:59 PM
Ignite Modification Date: 2026-03-08 @ 1:47 AM
Study NCT ID: NCT02608268
Status: TERMINATED
Last Update Posted: 2023-12-06
First Post: 2015-10-15
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Malignancies View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Solid tumors View
None Melanoma View
None Non small cell lung cancer View
None NSCLC View
None Renal cell carcinoma View
None RCC View
None Phase I-Ib/II View
None MBG453 View
None PDR001 View
None Checkpoint inhibitor View
None PD-1 View
None TIM-3 View